Thermo Fisher Scientific has received the US Food and Drug Administration (FDA) approval for its next-generation sequencing (NGS) based test as a companion diagnostic for various non-small cell lung cancer (NSCLC) therapies.

The Oncomine Dx Target Test is designed to simultaneously screen tumour samples for biomarkers associated with three FDA-approved NSCLC therapies.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The test simultaneously analyses 23 genes, of which three can now be used to identify patients who are eligible for potential treatment with the combined therapy of Tafinlar and Mekinist, XALKORI or IRESSA.

Contrary to other tests, which screen one biomarker at a time, the test is said to allow physicians to match patients to the therapies within days instead of weeks.

Thermo Fisher clinical next-generation sequencing and oncology president Joydeep Goswami said: "For people battling non-small cell lung cancer, time is critical and days matter.

"The Oncomine Dx Target Test rapidly guides oncologists toward the right targeted therapy, with the goal of improving patient outcomes and the cost-efficiency of treatments."

"The Oncomine Dx Target Test rapidly guides oncologists toward the right targeted therapy, with the goal of improving patient outcomes and the cost-efficiency of treatments."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Initially, the test is being offered by LabCorp's Diagnostics and Covance Businesses, NeoGenomics Laboratories and Cancer Genetics using Thermo Fisher's FDA 510(k) cleared Ion PGM Dx System.

Goswami further noted: "Thermo Fisher has entered into discussions with several pharmaceutical companies looking to use the panel for FDA-approved targeted therapy applications beyond lung cancer.”

Developed in partnership with Novartis and Pfizer, the test is based on Thermo Fisher's Ion AmpliSeq technology to facilitate tumour sample screening for several genetic markers with 10ng of nucleic acid, which is considered a benefit as samples from NSCLC patients are usually limited.

Image: FDA approves the Oncomine Dx Target Test. Photo: courtesy of PRNewsfoto/Thermo Fisher Scientific Inc.